Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$6.15 USD
+0.06 (0.99%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $6.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CAPR 6.15 +0.06(0.99%)
Will CAPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
Other News for CAPR
Is CAPR ready to move lower? Fell Below 20 Day Moving Average shows up after plummeting 8.42%
20 Day Moving Average Support appears for CAPR after 3.91% move
CAPR Crossed Above 20 Day Moving Average on September 19
CAPR forms Bollinger Band Squeeze on September 17
Is CAPR building pressure? Bollinger Band Squeeze shows up after rising 2.98%